Anticancer activity of metal complexes

involvement of redox processes

Ute Jungwirth, Christian R Kowol, Bernhard K Keppler, Christian G Hartinger, Walter Berger, Petra Heffeter

Research output: Contribution to journalReview article

235 Citations (Scopus)

Abstract

Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of "activation by reduction" as well as the "hard and soft acids and bases" theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.

Original languageEnglish
Pages (from-to)1085-127
Number of pages43
JournalAntioxidants & Redox Signaling
Volume15
Issue number4
DOIs
Publication statusPublished - 15 Aug 2011

Fingerprint

Coordination Complexes
Oxidation-Reduction
Metals
Homeostasis
Copper
Vanadium
Rhodium
Thioredoxins
Oncology
Molybdenum
Ruthenium
Gadolinium
Arsenic
Drug Delivery Systems
Manganese
Cobalt
Platinum
Gold
Pharmaceutical Preparations
Chemical properties

Keywords

  • Animals
  • Anticarcinogenic Agents/chemistry
  • Coordination Complexes/chemistry
  • Glutathione/metabolism
  • Homeostasis/drug effects
  • Humans
  • Ligands
  • Oxidation-Reduction/drug effects
  • Oxidative Stress
  • Thioredoxins/metabolism

Cite this

Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011). Anticancer activity of metal complexes: involvement of redox processes. Antioxidants & Redox Signaling, 15(4), 1085-127. https://doi.org/10.1089/ars.2010.3663

Anticancer activity of metal complexes : involvement of redox processes. / Jungwirth, Ute; Kowol, Christian R; Keppler, Bernhard K; Hartinger, Christian G; Berger, Walter; Heffeter, Petra.

In: Antioxidants & Redox Signaling, Vol. 15, No. 4, 15.08.2011, p. 1085-127.

Research output: Contribution to journalReview article

Jungwirth, U, Kowol, CR, Keppler, BK, Hartinger, CG, Berger, W & Heffeter, P 2011, 'Anticancer activity of metal complexes: involvement of redox processes', Antioxidants & Redox Signaling, vol. 15, no. 4, pp. 1085-127. https://doi.org/10.1089/ars.2010.3663
Jungwirth, Ute ; Kowol, Christian R ; Keppler, Bernhard K ; Hartinger, Christian G ; Berger, Walter ; Heffeter, Petra. / Anticancer activity of metal complexes : involvement of redox processes. In: Antioxidants & Redox Signaling. 2011 ; Vol. 15, No. 4. pp. 1085-127.
@article{6b4c7d3d87c6432b966338fe0db02b31,
title = "Anticancer activity of metal complexes: involvement of redox processes",
abstract = "Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of {"}activation by reduction{"} as well as the {"}hard and soft acids and bases{"} theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.",
keywords = "Animals, Anticarcinogenic Agents/chemistry, Coordination Complexes/chemistry, Glutathione/metabolism, Homeostasis/drug effects, Humans, Ligands, Oxidation-Reduction/drug effects, Oxidative Stress, Thioredoxins/metabolism",
author = "Ute Jungwirth and Kowol, {Christian R} and Keppler, {Bernhard K} and Hartinger, {Christian G} and Walter Berger and Petra Heffeter",
year = "2011",
month = "8",
day = "15",
doi = "10.1089/ars.2010.3663",
language = "English",
volume = "15",
pages = "1085--127",
journal = "Antioxidants & Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Anticancer activity of metal complexes

T2 - involvement of redox processes

AU - Jungwirth, Ute

AU - Kowol, Christian R

AU - Keppler, Bernhard K

AU - Hartinger, Christian G

AU - Berger, Walter

AU - Heffeter, Petra

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of "activation by reduction" as well as the "hard and soft acids and bases" theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.

AB - Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of "activation by reduction" as well as the "hard and soft acids and bases" theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.

KW - Animals

KW - Anticarcinogenic Agents/chemistry

KW - Coordination Complexes/chemistry

KW - Glutathione/metabolism

KW - Homeostasis/drug effects

KW - Humans

KW - Ligands

KW - Oxidation-Reduction/drug effects

KW - Oxidative Stress

KW - Thioredoxins/metabolism

U2 - 10.1089/ars.2010.3663

DO - 10.1089/ars.2010.3663

M3 - Review article

VL - 15

SP - 1085

EP - 1127

JO - Antioxidants & Redox Signaling

JF - Antioxidants & Redox Signaling

SN - 1523-0864

IS - 4

ER -